Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Harrington Discovery Institute Announces New Fund to Advance Breakthrough Discoveries into Novel Treatments

researchsnappy by researchsnappy
February 18, 2021
in Advertising Research
0
7.1% CAGR of Pharmaceutical Contract Development and Manufacturing Market is Expected to Reach USD 126.6 Billion by 2024- ReportsnReports
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

CLEVELAND, Feb. 18, 2021 /PRNewswire/ — The transatlantic, not-for-profit medical accelerator, Harrington Discovery Institute (HDI) at University Hospitals, has collaborated with leading venture investor, Advent Life Sciences (‘Advent’) in the launch of the Advent-Harrington Impact Fund.

Advent’s new impact fund, structured alongside Advent Life Sciences Fund III, brings a total of $215 million to advance breakthrough discoveries into novel treatments for the benefit of patients and society.

Advent-Harrington Impact Fund, a market rate investment fund, breaks new ground through a partnership with a novel philanthropic vehicle at Morgan Stanley Wealth Management (MS GIFT Cures powered by HDI). Profits from Advent-Harrington Impact Fund are shared with HDI to create the means to Sustainable Philanthropy through a virtuous cycle. In this way, financial returns to HDI catalyze additional drug development to address future unmet medical need. 

Advent is focused on building innovative life science companies in the UK, Europe and the US. The business model is based on best-in-class early stage science. The collaboration with HDI broadens the quality of investment in academic research and commercial drug development opportunities across the globe, while increasing the amount of capital available to support these projects.

“Advent’s focus on delivering new medicines for unmet medical needs closely aligns with Harrington’s mission. We are pleased to be able to expand Advent’s access to world-class academic science with high medical and commercial promise,” said Jonathan S. Stamler, MD, President, HDI, Robert S. and Sylvia K. Reitman Family Foundation Distinguished Professor of Cardiovascular Innovation and Professor of Medicine and of Biochemistry at University Hospitals and Case Western Reserve University.

Shahzad Malik, General Partner, Advent Life Sciences, said, “The last year reinforced the vital need to translate world class science into the discovery and development of new medicines to tackle devastating diseases. We are delighted to have partnered with Harrington Discovery Institute to provide translational finance that will deliver real impact to patients in addition to strong financial returns.”

Advent’s portfolio success stories over the last year include the sale of Advent-founded KaNDy Therapeutics to Bayer Pharmaceuticals for over $875 million bringing a non-hormonal treatment for symptoms of menopause closer to patients; Advent-founded Arrakis’ $190 million partnership deal with Roche to develop small molecule modulators of RNA; the NASDAQ IPO of Acutus Medical launching a best-in-class mapping technology and future ablation therapies for cardiac arrythmias; and notable follow-on financings including participating in a $60 million round for F2G Therapeutics, that also received Breakthrough Therapy Designation from the FDA for its novel class of anti-fungal treatments that address a very high unmet need.

“The need to deliver cures could not be greater. The Advent-Harrington Impact Fund recognizes this need and offers a new pathway to accelerate scientific breakthroughs into medicines for the benefit of patients,” added Dr. Stamler.

SOURCE Harrington Discovery Institute

Previous Post

Innovation in Resin Formulations Creates Opportunities for Plastic Pipe Use in Oil and Gas Settings

Next Post

Reimagining Equitable Applications and Awardee Selection in ACF’s Funded Opportunities

Next Post
Reimagining Equitable Applications and Awardee Selection in ACF’s Funded Opportunities

Reimagining Equitable Applications and Awardee Selection in ACF’s Funded Opportunities

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

How Dole Asia’s New $2 Million-A-Year Fund Is Seeking Solutions To End Malnutrition, Promote Sustainability

Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2020-2026 – NeighborWebSJ

Thursday’s Market Minute: Dips & Rips For Equities

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2021 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2021 researchsnappy.com